NIKKEI 225
39,014.20 -55.48 (-0.14%) HANG SENG
19,299.48 -336.74 (-1.71%) CRUDE OIL
79.22 -0.58 (-0.73%) GOLD FUTURES
2,418.30 -20.20 (-0.83%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
55,939.55 +3,133.75 (+5.93%)
Alimera Sciences, Inc. (ALIM)
- GuruFocus.com
Alimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...
Discover how Alimera Sciences achieved remarkable revenue growth and strategic advancements in Q1 2024.
- Zacks
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -200% and 2.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Alimera Sciences Reports First Quarter 2024 Results
Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a
